Extended Data Fig. 4: ApoE in GFAP⁺ cells and ApoE levels in CSF and plasma in Mrc1^Cre+/ApoE4 ^fl/fl and Mrc1^Cre+/ApoE3^fl/fl mice.

a-f. Triple or dual RNAScope in situ hybridization with Mrc1 mRNA probes (green in A–B), GFAP (gray in A–B and green in C-D), and ApoE (magenta), DAPI (blue) and the basal lamina marker laminin (gray in C-D). a, c. In vehicle-treated Mrc1^Cre+/AoE4^fl/fl (A) and Mrc1^Cre+/AoE3^fl/fl (C) mice, ApoE expression is found both in Mrc1⁺ (green, A) and GFAP⁺ (gray in A and green in C) cells. In tamoxifen (TAM)-treated Mrc1^Cre+/AoE4^fl/fl (B) and Mrc1^Cre+/AoE3^fl/f (D) mice, ApoE is deleted in Mrc1⁺ cells (B), but its expression is not affected in GFAP+ cells (B, D). Representative confocal images (A-D) from N = 3–5 mice/group. Scale bars = 20 μm. E–F. The numbers of GFAP⁺ and ApoE⁺GFAP⁺ cells are comparable in vehicle- and TAM-treated Mrc1^Cre+/ApoE4^fl/fl and Mrc1^Cre+/ApoE3^fl/fl mice (N = 5 mice/group; 2-3 sections/mice). G–H. ApoE levels in CSF (G) and plasma (H), quantified by MSD, are comparable in vehicle- and tamoxifen-treated Mrc1^Cre+/ApoE4^fl/fl and Mrc1^Cre+/ApoE3^fl/fl mice. N = 5/group. Data in E-H were analyzed using two-way ANOVA with Tukey’s test and are presented as mean±SEM. N = 5/group.

Source data